RITE3
Live / Allowed — Notice of allowance issued (as of 14 Oct 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 30 Aug 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98727351
- Mark type
- Stylized text
- Filed
- 30 Aug 2024
- Published for opposition
- 19 Aug 2025
- Attorney of record
- Ian W. Gillies
Goods and services
- Class 042 — Scientific and technological services: drug discovery, pharmaceutical drug development, and drug validation services in the field of targeted disease-causing or disease-associated protein degradation; pharmaceutical research and development services, in particular for identifying ubiquitin ligases; providing medical research and scientific information related to ubiquitin ligase identification and targeted disease-causing or disease-associated protein degradation in the fields of pharmaceuticals, biological life sciences, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, and medical research information related to targeted disease-causing or disease-associated protein degradation in the field of pharmaceutical and clinical trials via the internet; consulting services in the fields of pharmaceutical research, biological life sciences, pharmaceutical chemistry, biochemistry, biotechnology, clinical trials, all related to targeted disease-causing or disease-associated protein degradation; research and development of new products in the field of targeted disease-causing or disease-associated protein degradation and the identification of ubiquitin ligases; pharmaceutical, scientific, medical, and clinical research and development services in the field of targeted disease-causing or disease-associated protein degradation; providing information about scientific, pharmaceutical, clinical, and medical research, namely, drug discovery, development and validation information related to a method of ligase selection to discover molecules and drugs that cause targeted disease-causing or disease-associated protein degradation; Scientific and technological services, namely, technical biology consulting services, in particular for identifying ubiquitin ligases
Owner
- SEED Therapeutics US, Inc., King of Prussia, PA, US
- SEED Therapeutics US, Inc., King of Prussia, PA, US
Prosecution history
- 15 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 14 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Aug 2025 — PUBLISHED FOR OPPOSITION
- 13 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Mar 2025 — NON-FINAL ACTION E-MAILED
- 13 Mar 2025 — NON-FINAL ACTION WRITTEN
- 13 Mar 2025 — ASSIGNED TO EXAMINER
- 12 Mar 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 30 Aug 2024 — NEW APPLICATION ENTERED